How India Exports Famotidine to the World

In the United States, famotidine is approved by the Food and Drug Administration (FDA) for both prescription and over-the-counter (OTC) use. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for famotidine, indicating a competitive generic market. Notably, Teva Pharmaceuticals received approval for its ANDA (No. 075311) on April 16, 2001, and Apotex Inc. for its ANDA (No. 075611) on July 23, 2001. These approvals underscore the established presence of famotidine in the U.S. market.

The substantial export volume of famotidine from India to the United States, accounting for 84.0% of total exports, reflects the significant demand and acceptance of Indian-manufactured famotidine in the U.S. market. The presence of 152 active Indian exporters supplying to the U.S. indicates a robust and competitive supply chain.

In the European Union (EU), famotidine is subject to national marketing authorizations, with oversight by the European Medicines Agency (EMA). The EMA has conducted periodic safety update report single assessments (PSUSAs) for famotidine, with the most recent procedure (PSUSA/00001350/202209) resulting in a variation to the marketing authorization in June 2023. (ema.europa.eu) This indicates ongoing pharmacovigilance and regulatory scrutiny to ensure the safety and efficacy of famotidine-containing products in the EU.

In the United Kingdom (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the marketing authorization of medicinal products. Famotidine 40 mg Film Coated Tablets (PL 04569/0423) were granted authorization via an abridged standard application on July 2, 2001, demonstrating essential similarity to the reference product. (gov.uk) This reflects the established regulatory pathway for generic famotidine products in the UK.

Famotidine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The inclusion in the WHO Model List signifies recognition of famotidine's efficacy and safety profile. Additionally, famotidine formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and therapeutic equivalence across different markets.

In India, famotidine is classified as a Schedule H drug under the Drugs and Cosmetics Rules, 1945, indicating that it is available only by prescription. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including famotidine, to ensure affordability. Export of pharmaceutical products like famotidine requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and quality standards.

The primary patents for famotidine have expired, leading to a competitive generic market with multiple manufacturers producing and exporting the drug. This has resulted in increased accessibility and affordability of famotidine globally.

In June 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for famotidine-containing medicines to include warnings about potential drug interactions with posaconazole and certain tyrosine kinase inhibitors. (ema.europa.eu) This highlights the importance of continuous monitoring and updating of safety information for established drugs.

In September 2023, the NPPA revised the ceiling price for famotidine tablets in India, reflecting adjustments to ensure the drug remains affordable while considering manufacturing costs and market dynamics. This demonstrates the Indian government's commitment to balancing affordability with industry sustainability.

In November 2023, the FDA issued a guidance document outlining new requirements for the stability testing of famotidine formulations, aiming to enhance product quality and shelf-life standards. This move underscores the FDA's focus on ensuring the long-term efficacy and safety of pharmaceutical products.

In January 2024, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of famotidine, which reflects its continued relevance in treating acid-related disorders globally.

In March 2024, the CDSCO implemented stricter regulations for the export of pharmaceutical products, including famotidine, requiring additional quality certifications to enhance the credibility of Indian exports in international markets. This initiative aims to bolster the reputation of Indian pharmaceuticals and ensure compliance with global quality standards.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of APIs are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance is particularly concerning given that 58% of KSMs used for U.S.-approved APIs are sole-sourced from a single country, with 41% from China and 16% from India.

The COVID-19 pandemic and subsequent geopolitical tensions have exposed vulnerabilities in this supply chain. For instance, in June 2025, escalating conflicts in the Strait of Hormuz led to disruptions in the transportation of essential raw materials, causing delays and increased costs in pharmaceutical manufacturing. (pharmasource.global) Such events highlight the risks associated with over-reliance on specific countries for critical raw materials.

Our proprietary trade data indicates that the top five exporters of Famotidine from India account for 60.0% of the total export value, with VKT Pharma Private Limited alone contributing 18.3%. This high supplier concentration poses a significant risk; any operational or regulatory issues faced by these key players could disrupt the entire supply chain.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in October 2025, aiming to boost domestic production of APIs and KSMs. While this initiative is a step towards reducing dependency on imports, its effectiveness in diversifying the supplier base and enhancing supply chain resilience remains to be fully realized.

Geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts led to a near halt in maritime traffic, affecting the transportation of oil and essential raw materials. Similarly, disruptions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around the Cape of Good Hope, adding delays and increasing transportation costs.

These disruptions have cascading effects on the pharmaceutical industry, leading to increased costs and potential shortages. For example, the blockade of the Strait of Hormuz in March 2026 resulted in significant delays in the delivery of APIs and KSMs, impacting production schedules and escalating costs. (lemonde.fr)

• Diversify Supplier Base: Engage with a broader range of suppliers across different regions to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for APIs and KSMs to decrease reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to identify and address potential disruptions proactively.

• Develop Contingency Plans: Establish comprehensive contingency plans to manage supply chain disruptions caused by geopolitical events.

• Collaborate with Regulatory Bodies: Work closely with regulatory agencies to ensure compliance and address potential regulatory challenges promptly.

RISK_LEVEL: HIGH